United States Drug Patent D386849: Scope, Claims, Expiration, and Patent Landscape for the Liquid Applicator Design

United States Design Patent D386849 protects the ornamental appearance of a liquid applicator, not the liquid composition, therapeutic use, dispensing function, or manufacturing process. Its single claim covers the visual design shown in the patent drawings. Because D386849 is a pre-2015 U.S. design patent, its 14-year term has expired. It no longer creates a U.S. exclusionary right against competing applicators.

What does U.S. Design Patent D386849 protect?

D386849 claims:

"The ornamental design for a liquid applicator, as shown and described."

This is a design-patent claim. The legally relevant subject matter is the product's visual appearance as disclosed by the drawings. The patent does not claim a liquid formulation, an active pharmaceutical ingredient, a dosing regimen, a therapeutic indication, or a functional mechanism.

The patent's scope is therefore determined by:

The figures included in the patent;
The solid and broken lines used in those figures;
The overall visual impression of the applicator;
The ordinary observer test applied against the prior art.

Under 35 U.S.C. § 171, a design patent may protect a new, original, and ornamental design for an article of manufacture. The article identified by D386849 is a liquid applicator. The design right attaches to the appearance of the article, or to the claimed portion of it, rather than to the underlying method of operation.[1]

What is the single claim in D386849?

D386849 contains a single claim directed to the ornamental design shown and described. This standard design-patent wording incorporates the patent drawings into the claim.

The claim should not be read as covering every product that dispenses liquid. It covers only a liquid applicator that creates substantially the same overall visual impression as the patented design when compared with the relevant prior art.

A device can have the same purpose and still avoid infringement if its appearance differs sufficiently. Conversely, a device does not avoid infringement merely because it has a different name, internal mechanism, or liquid product if its visual appearance is substantially the same.

Is D386849 a utility patent or a design patent?

D386849 is a U.S. design patent. The "D" prefix distinguishes it from utility patents and plant patents.

Attribute	D386849
Patent type	U.S. design patent
Claimed subject	Ornamental design for a liquid applicator
Claim count	One
Functional claims	None
Composition claims	None
Method-of-use claims	None
Manufacturing claims	None
Drawing dependence	High
Original term	14 years from grant for pre-2015 design patents
Current status	Expired by term
Pharmaceutical exclusivity	None created by the claim

The patent may have been commercially relevant to packaging, cosmetics, medical devices, laboratory products, or other liquid-dispensing products. The claim itself does not identify a drug, biologic, active ingredient, indication, dosage form, or FDA-regulated therapeutic product.

When did D386849 expire?

D386849 was granted under the pre-December 18, 2013 design-patent term regime. Its term was 14 years from the date of grant under the law then in effect. The patent therefore expired 14 years after its issue date.[2]

Public patent records identify D386849 as a late-1990s U.S. design patent. Its enforceable term ended no later than the corresponding 14-year anniversary of issuance, placing expiration in the early 2010s. A design patent that has expired by term cannot support a new infringement suit based on post-expiration commercial activity.

Legal question	Result
Is D386849 currently enforceable?	No
Can the patent block a generic or competitor today?	No
Can the expired patent support a Paragraph IV challenge?	No
Can the patent create current Orange Book protection?	No
Can the patent support a current injunction?	No
Can historical conduct during the enforceable term be relevant?	Potentially, subject to limitation periods and case-specific facts

Expiration does not erase the historical patent record. It ends the patent owner's ability to use the patent as an exclusionary right against future conduct.

What is the legal scope of the D386849 liquid applicator claim?

The scope is visual and comparative. Courts generally evaluate design-patent infringement under the ordinary observer test. The question is whether an ordinary observer, familiar with the prior art, would be deceived into purchasing the accused product believing it to be the patented design.[3]

The analysis considers the design as a whole. Individual elements such as a cap, barrel, neck, tip, flange, shoulder, or opening may matter, but the claim does not ordinarily grant ownership over common components in isolation unless the drawings make those components distinctive.

Overall visual impression

The principal scope questions are likely to include:

The overall silhouette of the applicator;
The relative proportions of the main body and applicator tip;
The shape and profile of the cap or cover;
The transition between the body and dispensing end;
The arrangement of ornamental contours;
The presence or absence of surface ornamentation;
The visual relationship between the applicator and its closure.

A competing product with a different internal reservoir or dispensing valve could still raise design-patent concerns if its external appearance is substantially the same. A product with the same liquid-dispensing function but a materially different external configuration would generally present a lower design-infringement risk.

Functional features and design-patent limits

Design-patent protection does not extend to features dictated solely by function. A liquid applicator may require certain dimensions or shapes to connect to a container, deliver a liquid, or permit user handling. Those functional constraints can narrow the practical scope of the design.

The patent nevertheless may protect an ornamental configuration that performs a function. The relevant distinction is whether the claimed appearance is ornamental or whether the shape is dictated by the article's function.[4]

What do the drawings contribute to D386849 claim construction?

The drawings are central to D386849. The written claim contains almost no verbal limitation beyond the article designation and the reference to the drawings.

For a design patent, the figures can disclose:

The claimed exterior surfaces;
The relative size of components;
The shape of the applicator tip;
The contour of the body;
The visual treatment of the cap or handle;
Whether a portion is shown in broken lines and therefore not part of the claimed design.

If the patent drawings contain no broken-line disclaimer, the entire illustrated configuration may be relevant. If broken lines identify environmental or unclaimed portions, the enforceable design is limited to the solid-line subject matter.

The patent drawings should therefore be reviewed figure by figure before making a product-clearance decision. A text-only claim summary cannot resolve whether a particular cap, tip, or container portion is claimed.

What patent rights did D386849 provide for pharmaceutical products?

D386849 did not provide drug patent protection in the conventional pharmaceutical sense.

It did not claim:

A new chemical entity;
A drug substance;
A pharmaceutical composition;
A formulation;
A medical indication;
A route of administration;
A dosing schedule;
A manufacturing process;
A sterile delivery method;
A combination therapy.

The patent could have covered the appearance of a package component or applicator used with a pharmaceutical product. That would be packaging or device-design protection, not protection for the drug itself.

A sponsor could separately own utility patents covering the applicator's delivery mechanism, container closure, dose control, sterilization, or formulation compatibility. Those rights would need to be identified in separate patent documents. They are not included in the D386849 claim.

Does D386849 appear in the FDA Orange Book?

D386849 is not an Orange Book drug patent.

The FDA Orange Book lists patents submitted by applicants for approved prescription drug products under applicable FDA regulations. Listed patents generally concern the drug substance, drug product, or approved method of use. A standalone ornamental design patent for a liquid applicator is not the normal basis for Orange Book listing.[5]

Orange Book issue	D386849 status
Drug substance patent	No
Drug product or formulation patent	No
Method-of-use patent	No
Design patent	Yes
Orange Book relevance	None apparent from the claim
Paragraph IV relevance	None
30-month stay potential	None based on D386849

A liquid applicator could be part of a drug-device combination product, but that does not convert an ornamental design patent into a drug patent. Separate regulatory and patent analysis would be required for any associated product.

Are there Paragraph IV challenges to D386849?

No current Paragraph IV challenge should attach to D386849.

Paragraph IV certifications apply to patents listed in the Orange Book for an approved drug product. D386849 is a design patent directed to an applicator's appearance. It does not claim a drug product or method of use and does not provide a typical basis for an abbreviated new drug application patent certification.

A generic applicant could still face separate patents covering:

The active ingredient;
The formulation;
The container-closure system;
The applicator's mechanical operation;
A drug-device combination;
An approved method of treatment.

Those rights would arise from other patents, not from D386849.

What is the patent landscape around a liquid applicator?

The relevant landscape has several distinct patent categories. D386849 occupies only the ornamental-design category.

Patent category	Typical subject matter	Relationship to D386849
Design patents	Shape, surface ornamentation, visual configuration	Same category
Utility patents	Valves, reservoirs, dose control, applicator mechanics	Separate rights
Formulation patents	Viscosity, stability, excipients, delivery composition	Not covered
Method-of-use patents	Applying a product for a therapeutic or cosmetic purpose	Not covered
Packaging patents	Container, closure, tamper evidence, assembly	Potentially adjacent
Manufacturing patents	Molding, assembly, filling, sterilization	Not covered
Trademark rights	Product names, logos, trade dress	Separate rights
Regulatory exclusivity	NCE, orphan, pediatric, clinical investigation exclusivity	Not created

What formulations are protected by D386849?

None. The patent does not claim any liquid formulation.

The claim would not protect a particular viscosity, solvent, active ingredient, preservative, polymer, suspension, emulsion, or combination of excipients. A competitor could use the same liquid, a different liquid, or no therapeutic liquid at all without implicating the formulation subject matter of D386849.

What manufacturing processes are protected?

None are claimed. The patent does not cover injection molding, blow molding, machining, assembly, filling, sterilization, coating, or quality-control processes.

A manufacturer could use a different production method and still produce a potentially similar-looking article. Conversely, a manufacturer could use the same production process for a visually different applicator without implicating the expired design patent.

How strong was the D386849 patent estate?

The D386849 estate is narrow in claim count and historically limited in subject matter. Its principal strengths were:

Clear identification of the product category;
Visual protection for the disclosed configuration;
Potential value against substantially similar commercial designs during the term;
No requirement to prove a functional mechanism.

Its principal limitations were:

One design claim;
Dependence on the figures;
No formulation or therapeutic coverage;
No protection for alternative visual embodiments not disclosed;
Potential narrowing from functional aspects and prior art;
Expiration after 14 years.

Because the patent has expired, its current commercial strength is zero as an exclusionary right. Its residual value is limited to historical portfolio analysis, product-line research, prior-art review, and possible evidence concerning the development or branding of an applicator.

Which companies could challenge or design around D386849?

No current company needs to challenge D386849 to commercialize a competing liquid applicator because the patent is expired.

During the term, a competitor could have pursued several strategies:

Use a materially different external silhouette.
Alter the proportions of the applicator body and tip.
Change the cap, shoulder, neck, or closure geometry.
Use contrasting surface ornamentation.
Adopt a different arrangement of visible components.
Seek a declaratory judgment or defend against an infringement claim.
Challenge validity based on prior art, lack of ornamentality, lack of novelty, or functionality.

A modern competitor's primary risk would come from later unexpired design or utility patents, trade dress, contractual restrictions, or regulatory requirements. D386849 itself does not create current launch risk.

Did D386849 affect generic launch timing?

D386849 did not create a generic drug-launch barrier.

It could not independently establish:

New chemical entity exclusivity;
Five-year Hatch-Waxman exclusivity;
Orphan-drug exclusivity;
Pediatric exclusivity;
A 30-month Paragraph IV stay;
A formulation patent term;
A method-of-use patent term.

A generic drug company evaluating a liquid dosage form would need to review the drug's Orange Book-listed patents and FDA exclusivity dates. A company evaluating only the applicator would need to review active device, packaging, design, trademark, and trade-dress rights. D386849 would not be a current obstacle.

What litigation and settlement issues affect D386849?

There is no current litigation consequence from an expired design patent unless the dispute concerns conduct during the enforceable term or historical damages.

A historical design-patent case would likely have involved:

Claim construction based on the drawings;
Comparison with the accused applicator;
The ordinary observer test;
Analysis of the prior art;
Potential invalidity defenses;
Damages for sales during the patent term.

There is no basis to infer a settlement agreement, license, or litigation involving D386849 solely from the claim language. A commercial license would also have limited current value unless it includes separate rights, confidential know-how, trademarks, or later patents.

How does D386849 compare with later design patents?

D386849 has the shorter 14-year term applicable to older design patents. Design patents issued from applications filed on or after May 13, 2015 generally receive a 15-year term from grant under the Hague-related statutory changes.[6]

Issue	D386849	Later U.S. design patent
Claim format	Ornamental design shown and described	Usually similar
Term	14 years from grant	Generally 15 years from grant for qualifying post-2015 applications
Scope	Drawing-dependent visual design	Drawing-dependent visual design
Drug claims	None	None unless separately patented
Orange Book listing	Not applicable	Generally not applicable as a standalone design patent
Current enforceability	Expired	Depends on issue date and maintenance status, with no maintenance fees for design patents

The comparison does not mean later design patents automatically cover the same subject matter. Each design patent must be compared on its drawings, claimed portions, filing history, and prior art.

What is the commercial exposure associated with D386849?

Current revenue exposure is zero from the patent itself because the patent cannot block sales after expiration.

Historical exposure may have existed for products that copied the patented visual configuration during the enforceable period. The economic value would have depended on:

Applicator unit volume;
Product price and margin;
The importance of the applicator's appearance to consumer demand;
Availability of non-infringing alternatives;
The patent owner's market share;
The duration of any alleged infringement;
Evidence of copying or commercial substitution.

No reliable revenue estimate can be assigned from the claim alone. The patent covers an appearance, not a defined product line or revenue stream.

Key Takeaways

D386849 is a U.S. design patent for the ornamental design of a liquid applicator.
Its single claim is limited to the visual configuration shown in the drawings.
It does not protect a drug, formulation, active ingredient, method of treatment, or dispensing mechanism.
The patent had a 14-year term because it belongs to the pre-2015 design-patent regime.
D386849 is expired and cannot create current launch, generic, or licensing barriers.
It is not an ordinary Orange Book patent and does not support a Paragraph IV challenge.
Current commercial risk must be assessed against later design patents, utility patents, trademarks, trade dress, and regulatory requirements.
Any historical infringement analysis would turn on the figures, prior art, accused product appearance, and the period of alleged conduct.

FAQs About U.S. Design Patent D386849

Can a company sell a liquid applicator that looks similar to D386849?

Yes, D386849 is expired. A current product is not subject to infringement liability based solely on that patent. Other active patents, trademarks, or trade-dress rights could still apply.

Does D386849 protect a mascara, eye-drop, or topical-drug applicator?

The claim does not identify a specific product category beyond a liquid applicator. Its protection is determined by the drawings and overall visual appearance, not by a therapeutic or cosmetic indication.

Can D386849 be listed in the Orange Book?

A standalone ornamental design patent for an applicator is not the type of patent ordinarily listed to support drug-product exclusivity or a Paragraph IV certification.

Does expiration of D386849 invalidate the applicator design?

No. Expiration ends patent exclusivity. It does not prevent the owner from using the design or affect whether the design remains aesthetically or commercially valuable.

What patent should be reviewed alongside D386849 for a combination product?

The relevant portfolio should include active patents covering the formulation, applicator mechanism, container closure, dose delivery, manufacturing process, approved method of use, and any later design or packaging configuration.

References

United States Code. (2024). 35 U.S.C. § 171: Patents for designs. U.S. Government Publishing Office.
United States Code. (2024). 35 U.S.C. § 173: Term of design patent. U.S. Government Publishing Office.
Egyptian Goddess, Inc. v. Swisa, Inc., 543 F.3d 665 (Fed. Cir. 2008) (en banc).
Gorham Co. v. White, 81 U.S. 511 (1871).
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
United States Patent and Trademark Office. (2024). Manual of Patent Examining Procedure, Chapter 1500: Design patents.

Details for Patent: D386849

Summary for Patent: D386849